Hypertension
Conditions
Interventions
Part I: Self-controlled test (single arm):Patients with hypertension whose blood pressure is not up to standard for more than 4 weeks are treated with the initial drug regimen, and the mode of "antihy
Part II: Experimental group:Medication Antihypertensive Xiaoda management mode combined with Baduanjin
Part II: Control group:Medication Traditional mode of presentation
Sponsors
Guizhou Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Self-controlled before-and-after studies and randomized controlled studies must all meet the following conditions: 1. Be between 30-65 years old; 2. Patients diagnosed with essential hypertension have intraclinic blood pressure before drug treatment: systolic blood pressure is in the range of 160-190mmHg and/or diastolic blood pressure is in the range of 100-120mmHg; 3. After more than 4 weeks of drug treatment, the family/office and ambulatory blood pressure are not up to standard and are within the above range (exceeding the target systolic/diastolic blood pressure< = 15/10mmHg, i.e., home blood pressure 135-150/85-95mmHg or office blood pressure 140-155/90-100mmHg, and ambulatory blood pressure is 130-145/80-90mmHg or 135-150/85-95mmHg during the day and 120-135/ at night/ 70-80mmHg); 4. I have a smart phone and can use it proficiently, can use the upper arm electronic sphygmomanometer to measure blood pressure at home independently, and upload blood pressure data using the blood pressure Xiaoda management platform, and can cooperate with the completion of the whole clinical follow-up; 5. Conduct Baduanjin training for patients in advance, and complete the standard patients of quality control; 6. Voluntarily sign the informed consent form, accept random assignment, and are expected to have good compliance.
Exclusion criteria
Exclusion criteria: Self-controlled before-and-after studies and randomized controlled studies must all meet the following conditions: 1. Age and office blood pressure did not meet the inclusion criteria; 2. Secondary hypertension that has been clearly diagnosed, including: primary hyperaldosteronism, Cushing's syndrome, pheochromocytoma, renal artery stenosis, reninoma, coarctation of the aorta, etc. 3. History of ischemic or hemorrhagic stroke within 3 months (excluding lacunar cerebral infarction and TIA). 4. Hospitalization for myocardial infarction or unstable angina pectoris, or coronary revascularization (PCI or CABG) within 3 months. 5. History of aortic dissection/dissection aneurysm rupture. 6. Chronic heart failure worsening at the time of hospitalization or admission to NYHA class III-IV heart failure within 3 months. 7. History of persistent atrial fibrillation, atrial flutter or other severe arrhythmias at the time of admission (including: slow sinus, diseased sinus, high-grade atrioventricular block, frequent premature ventricular syndrome, etc.). 8. Severe liver disease or liver dysfunction: AST, ALT, or ALP > 5ULN (5 times the upper limit of normal), or BIL>3ULN (3 times the upper limit of normal). 9. End-stage renal disease or eGFR 2.5 mg/dL [>221 µmol/L]). 10. Patients with severe physical diseases such as malignant tumors and autoimmune diseases. 11. Severe cognitive impairment or mental disorder. 12. Pregnant and lactating women. 13. Participate in other clinical trials. 14. Patients with other diseases who cannot complete Baduanjin. 15. People with cognitive impairments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demographic information;Diagnosis and history of the disease;Laboratory test information;The number of times and compliance with the eight duanjin plays per week; | — |
Countries
China
Contacts
Public ContactLi Xiangchuan
Guizhou Provincial People's Hospital
Outcome results
None listed